ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
While the role of ASLX1 in haematopoiesis and leukaemia has been heavily studied, the role of ASLX2 is unclear. Here the authors show that ASLX2 is required for normal haematopoietic stem cell self-renewal whereas Asxl2 loss promotes leukemogenesis, thus explaining the frequently observed mutations...
Guardado en:
Autores principales: | Jean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, Nicolas Duployez, Eunhee Kim, Stanley Chun-Wei Lee, Benjamin H. Durham, Young Rock Chung, Hana Cho, Xiao Jing Zhang, Akihide Yoshimi, Andrei Krivtsov, Richard Koche, Eric Solary, Amit Sinha, Claude Preudhomme, Omar Abdel-Wahab |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4858a0bedd1541a2a819f03ad5087413 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1
por: Salima Daou, et al.
Publicado: (2018) -
BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice
por: Stephanie Perkail, et al.
Publicado: (2020) -
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Shuhei Asada, et al.
Publicado: (2018) -
Breast cancer immunophenotype and its relationship with haematopoiesis
por: Denis A. Ryabchikov, et al.
Publicado: (2021) -
Loss of Asxl2 leads to myeloid malignancies in mice
por: Jianping Li, et al.
Publicado: (2017)